Immune checkpoint blockade therapy, which mostly targets PD-1/PD-L1 and CTLA-4/CD28 pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new strategy against cancer [49]. This evidence concerns the gene CD274 and cancer.